Area of research
Oncology · Immunology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, CAR-T cell therapy research, and Immune Cell Function and Interaction.
Thrombospondin-1–CD47 signaling contributes to the development of T cell exhaustion in cancer
Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models
EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function
Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment
Modulating Treg stability to improve cancer immunotherapy
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors
A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance
Hallmarks of Resistance to Immune-Checkpoint Inhibitors
Fundamental immune–oncogenicity trade-offs define driver mutation fitness
MAIT and Vδ2 unconventional T cells are supported by a diverse intestinal microbiome and correlate with favorable patient outcome after allogeneic HCT
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions
Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade
508 Generalizability of predictive versus prognostic indicators from published transcriptomic associations with tumor response to immune checkpoint inhibition
Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors
CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours
Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma
Supporting the Next Generation of Scientists to Lead Cancer Immunology Research
CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism
Oxidized Lipids and CD36-Mediated Lipid Peroxidation in CD8 T Cells Suppress Anti-Tumor Immune Responses
Rational design of anti-GITR-based combination immunotherapy
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
Non-conventional Inhibitory CD4+Foxp3−PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity
Non-conventional Inhibitory CD4+Foxp3–PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer